OMAR Opioid Use Disorder

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Yale University
Study ID
NCT05683184
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Control
  • Opioid Use Disorder

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • [11C]OMAR — DRUG
    For each \[11C\]OMAR PET scan, up to 20 mCi of \[11C\]OMAR will be administered.

Study Details

The goal of this research study is to examine the endocannabinoid (eCB) function in vivo in individuals with opioid use disorder (OUD) by measuring cannabinoid receptor 1 (CB1R) availability.

Key Dates

Start date
Mar 10, 2023
Status verified
Apr 2026
Primary completion
Dec 15, 2026
Completion
Dec 15, 2026

Study Design

Enrollment
30 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Other: Healthy Volunteers
    Healthy volunteers with no current or past major medical or psychiatric history
  • Other: Opioid Use Disorder
    Patients diagnosed with opioid use disorder

Primary Outcome Measure

CB1R Availability [ Time Frame: One time within 4 weeks of screening ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Connecticut Mental Health Center, Clinical Neuroscience Research UnitNew HavenConnecticut06519
Angelina Contreras, BS
[email protected]
203-626-1105
Anahita Bassir Nia, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in New Haven, CT

By research site
Connecticut Mental Health Center, Clinical Neuroscience Research Unit· New Haven, CT

Related Studies